Danni M - Search Results

1

Parvovirus B19 infection in a patient with multiple sclerosis treated with ocrelizumab.

Lattanzi S, Carlini G, Acciarri MC, Danni M, Silvestrini M. Lattanzi S, et al. Among authors: danni m. Acta Neurol Belg. 2020 Feb;120(1):231-232. doi: 10.1007/s13760-019-01227-y. Epub 2019 Oct 25. Acta Neurol Belg. 2020. PMID: 31654393 No abstract available.

2

COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.

Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A; OCREVID study group on behalf of the Italian MS Register. Bisecco A, et al. J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20. J Neurol. 2024. PMID: 37982852 Free PMC article.

3

A multidimensional assessment of multiple sclerosis: relationships between disability domains.

Provinciali L, Ceravolo MG, Bartolini M, Logullo F, Danni M. Provinciali L, et al. Among authors: danni m. Acta Neurol Scand. 1999 Sep;100(3):156-62. doi: 10.1111/j.1600-0404.1999.tb00731.x. Acta Neurol Scand. 1999. PMID: 10478578

4

Percutaneous transluminal angioplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis: dichotomy between subjective and objective outcome scores.

Zagaglia S, Balestrini S, Perticaroli E, Danni MC, Luzzi S, Silvestrini M, Provinciali L. Zagaglia S, et al. Among authors: danni mc. Neurol Sci. 2013 Dec;34(12):2205-10. doi: 10.1007/s10072-013-1450-5. Epub 2013 May 10. Neurol Sci. 2013. PMID: 23660636

5

Prediction of disability progression in fingolimod-treated patients.

Lattanzi S, Danni M, Cerqua R, Taffi R, Provinciali L, Silvestrini M. Lattanzi S, et al. Among authors: danni m. J Neurol Sci. 2015 Nov 15;358(1-2):432-4. doi: 10.1016/j.jns.2015.09.010. Epub 2015 Sep 6. J Neurol Sci. 2015. PMID: 26362335

6

Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.

Lattanzi S, Cagnetti C, Danni M, Provinciali L, Silvestrini M. Lattanzi S, et al. Among authors: danni m. J Neurol. 2017 Aug;264(8):1697-1704. doi: 10.1007/s00415-017-8505-0. Epub 2017 May 10. J Neurol. 2017. PMID: 28492970 Review.

7

Persistence to oral disease-modifying therapies in multiple sclerosis patients.

Lattanzi S, Danni M, Taffi R, Cerqua R, Carlini G, Pulcini A, Provinciali L, Silvestrini M. Lattanzi S, et al. Among authors: danni m. J Neurol. 2017 Nov;264(11):2325-2329. doi: 10.1007/s00415-017-8595-8. Epub 2017 Aug 22. J Neurol. 2017. PMID: 28831550

8

Sleep in multiple sclerosis patients treated with interferon beta: an actigraphic study.

Rocchi C, Pulcini A, Vesprini C, Totaro V, Viticchi G, Falsetti L, Danni MC, Bartolini M, Silvestrini M, Buratti L. Rocchi C, et al. Among authors: danni mc. Neurol Res. 2020 Sep;42(9):744-748. doi: 10.1080/01616412.2020.1773629. Epub 2020 Jun 10. Neurol Res. 2020. PMID: 32520662

9

Cerebral hemodynamics in patients with multiple sclerosis.

Lattanzi S, Acciarri MC, Danni M, Taffi R, Cerqua R, Rocchi C, Silvestrini M. Lattanzi S, et al. Among authors: danni m. Mult Scler Relat Disord. 2020 Sep;44:102309. doi: 10.1016/j.msard.2020.102309. Epub 2020 Jun 17. Mult Scler Relat Disord. 2020. PMID: 32619964

10

Long-term outcome in multiple sclerosis patients treated with fingolimod.

Lattanzi S, Rocchi C, Danni M, Taffi R, Cerqua R, Carletti S, Silvestrini M. Lattanzi S, et al. Among authors: danni m. Mult Scler Relat Disord. 2020 Oct;45:102416. doi: 10.1016/j.msard.2020.102416. Epub 2020 Jul 21. Mult Scler Relat Disord. 2020. PMID: 32721897

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters